Gate Booster 第 4 期:发帖瓜分 1,500 $USDT
🔹 发布 TradFi 黄金福袋原创内容,可得 15 $USDT,名额有限先到先得
🔹 本期支持 X、YouTube 发布原创内容
🔹 无需复杂操作,流程清晰透明
🔹 流程:申请成为 Booster → 领取任务 → 发布原创内容 → 回链登记 → 等待审核及发奖
📅 任务截止时间:03月20日16:00(UTC+8)
立即领取任务:https://www.gate.com/booster/10028?pid=allPort&ch=KTag1BmC
更多详情:https://www.gate.com/announcements/article/50203
No approved treatment for this lung disease cough. A new pill now heads into Phase 3 trials
Trevi Therapeutics announced the completion of its End-of-Phase 2 meeting with the FDA, gaining alignment for its development program for Haduvio (nalbuphine ER oral) to treat idiopathic pulmonary fibrosis (IPF)-related chronic cough. The company plans to conduct two pivotal Phase 3 trials in parallel, starting in Q2 2026 and H2 2026, alongside remaining Phase 1 studies to support a New Drug Application (NDA). These trials will evaluate a 54 mg BID dose, using 24-hour cough frequency as the primary endpoint.